- Home
- DNLI vs DYN Comparison
DNLI vs DYN Comparison
Compare DNLI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- DYN
- Stock Information
- Founded
- DNLI 2013
- DYN 1984
- Country
- DNLI United States
- DYN United States
- Employees
- DNLI N/A
- DYN N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- DYN Medicinal Chemicals and Botanical Products
- Sector
- DNLI Health Care
- DYN Health Care
- Exchange
- DNLI Nasdaq
- DYN Nasdaq
- Market Cap
- DNLI 2.1B
- DYN 1.9B
- IPO Year
- DNLI 2017
- DYN 2020
- Fundamental
- Price
- DNLI $15.42
- DYN $13.06
- Analyst Decision
- DNLI Strong Buy
- DYN Strong Buy
- Analyst Count
- DNLI 15
- DYN 14
- Target Price
- DNLI $33.50
- DYN $34.93
- AVG Volume (30 Days)
- DNLI 2.1M
- DYN 2.4M
- Earning Date
- DNLI 11-05-2025
- DYN 11-11-2025
- Dividend Yield
- DNLI N/A
- DYN N/A
- EPS Growth
- DNLI N/A
- DYN N/A
- EPS
- DNLI N/A
- DYN N/A
- Revenue
- DNLI N/A
- DYN N/A
- Revenue This Year
- DNLI N/A
- DYN N/A
- Revenue Next Year
- DNLI $95,463.19
- DYN N/A
- P/E Ratio
- DNLI N/A
- DYN N/A
- Revenue Growth
- DNLI N/A
- DYN N/A
- 52 Week Low
- DNLI $10.57
- DYN $6.36
- 52 Week High
- DNLI $33.33
- DYN $35.90
- Technical
- Relative Strength Index (RSI)
- DNLI 62.72
- DYN 52.74
- Support Level
- DNLI $12.58
- DYN $12.33
- Resistance Level
- DNLI $15.75
- DYN $13.07
- Average True Range (ATR)
- DNLI 0.68
- DYN 0.70
- MACD
- DNLI 0.24
- DYN -0.12
- Stochastic Oscillator
- DNLI 89.59
- DYN 55.34
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.